Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Fish and Richardson
Novartis
Express Scripts
Harvard Business School
Cipla
Citi
Fuji
Moodys
AstraZeneca

Generated: February 23, 2018

DrugPatentWatch Database Preview

Details for Patent: 9,216,179

« Back to Dashboard

Which drugs does patent 9,216,179 protect, and when does it expire?

Patent 9,216,179 protects DUZALLO and ZURAMPIC and is included in two NDAs.

This patent has five patent family members in four countries.
Summary for Patent: 9,216,179
Title:Treatment of gout and hyperuricemia
Abstract: Sodium 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylt- hio)acetate is described. In addition, pharmaceutical compositions and uses of such compositions for the treatment of a variety of diseases and conditions are described.
Inventor(s): Miner; Jeffrey (San Diego, CA), Girardet; Jean-Luc (San Diego, CA), Quart; Barry D. (Encinitas, CA)
Assignee: ARDEA BIOSCIENCES, INC. (San Diego, CA)
Application Number:13/704,192
Patent Claim Types:
see list of patent claims
Use;

Drugs Protected by US Patent 9,216,179

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Ironwood Pharms Inc DUZALLO allopurinol; lesinurad TABLET;ORAL 209203-001 Aug 18, 2017 RX Yes No ➤ Sign Up ➤ Sign Up TREATMENT OF HYPERURICEMIA ASSOCIATED WITH GOUT IN PATIENTS WHO HAVE NOT ACHIEVED TARGET SERUM URIC ACID LEVELS WITH A MEDICALLY APPROPRIATE DAILY DOSE OF ALLOPURINOL ALONE ➤ Sign Up
Ironwood Pharms Inc DUZALLO allopurinol; lesinurad TABLET;ORAL 209203-002 Aug 18, 2017 RX Yes Yes ➤ Sign Up ➤ Sign Up TREATMENT OF HYPERURICEMIA ASSOCIATED WITH GOUT IN PATIENTS WHO HAVE NOT ACHIEVED TARGET SERUM URIC ACID LEVELS WITH A MEDICALLY APPROPRIATE DAILY DOSE OF ALLOPURINOL ALONE ➤ Sign Up
Ironwood Pharms Inc ZURAMPIC lesinurad TABLET;ORAL 207988-001 Dec 22, 2015 RX Yes Yes ➤ Sign Up ➤ Sign Up COADMINISTERING WITH ALLOPURINOL TO REDUCE SERUM URIC ACID (SUA) BELOW 4 MG/DL; BELOW 6MG/DL IN PATIENTS HAVING URIC ACID DEPOSITS; AND/OR BELOW 6MG/DL WITH SUA INTRADAY CHANGE MORE THAN 50% AND/OR ADVERSE EVENT RATE LESS THAN 15% ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 9,216,179

PCT Information
PCT FiledJune 14, 2011PCT Application Number:PCT/US2011/040398
PCT Publication Date:December 22, 2011PCT Publication Number: WO2011/159732

International Patents Family Members for US Patent 9,216,179

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Canada 2802407 ➤ Sign Up
European Patent Office 2582683 ➤ Sign Up
Japan 2013528650 ➤ Sign Up
Japan 5964821 ➤ Sign Up
World Intellectual Property Organization (WIPO) 2011159732 ➤ Sign Up
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cerilliant
Citi
QuintilesIMS
Julphar
Medtronic
AstraZeneca
UBS
Mallinckrodt
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot